ѻý

Broader Cancer Risk With CAR-T? AI for Physician Burnout; 'Lollipops' ID Oral Cancer

<ѻý class="mpt-content-deck">— News, features, and commentary about cancer-related issues
MedpageToday
Onco Break over a computer rendering of a cancer cell.

T-cell malignancies represent a small fraction of in patients treated with CAR T-cell therapy. (American Society of Hematology)

In an , the American Society of Clinical Oncology has recommended capivasertib (Truqap) plus fulvestrant for hormone receptor-positive/HER2-negative metastatic breast cancer with PIK3CA or AKT1 mutations or PTEN inactivation.

Cloud-based software company Salesforce announced the rollout of Einstein Copilot: Health Actions, the first of that will automate many of the administrative duties that drive physician burnout. (CNBC)

The 2024 version of , coinciding with the NCAA's "March Madness" basketball tournament, challenges readers to choose the best drug name among recent FDA approvals. (FiercePharma)

A recently discovered bacterium has two subspecies, one of which appears to from treatments. (NBC News, Nature)

The FDA announced (Elahere) for previously treated folate receptor-positive, platinum-resistant ovarian cancer.

Older patients with live longer than ever with stem cell transplants. (American Association for Cancer Research)

Many lack adequate safeguards to prevent mass generation of health misinformation. (The BMJ)

Hydrogel "lollipops" have shown early promise for diagnosing . (University of Birmingham, BBC)

Bristol Myers Squibb announced that the immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival in as compared with targeted therapy.

Electroencephalography showed promising for helping at least some patients avoid MRI and lumbar puncture to diagnose and . (American Society of Hematology)

Merck announced that a phase III trial in showed no improvement in survival with pembrolizumab (Keytruda) plus maintenance therapy with olaparib (Lynparza).

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined ѻý in 2007.